Company news
Arovella Therapeutics Limited news in 2022
Arovella Therapeutics Limited's news releases, calls and decks from 2022, newest first.
R&D Tax Incentive refund received
November 29, 2022
Europe Patent granted for iNKT Cell Therapy Platform
November 6, 2022
Arovella to close its Perth OroMist R&D Facility
October 25, 2022
Preclinical trial of ALA iNKT therapy and IMU onCARlytics
September 26, 2022
Preliminary Final Report
August 31, 2022
Quarterly Appendix 4C and Activities Report
July 28, 2022
Sumatriptan Update
June 27, 2022
ZolpiMist Launch Australia
June 22, 2022
Adopts WEF Framework For ESG Reporting
June 7, 2022
Services Agreement with Q-Gen for CAR19-iNKT manufacture
April 20, 2022
Anagrelide patent for the United States
April 5, 2022
Arovella Therapeutics: Proposed issue of securities - ALA
March 17, 2022
Application for quotation of securities - ALA
March 16, 2022
Update - Proposed issue of securities - ALA
February 28, 2022
Arovella SPP Closed early over subscribed
February 21, 2022
Investor Presentation
January 31, 2022
SPP Offer Booklet
January 23, 2022
Arovella Completes $4.57M Placement & Launches $1.5M SPP
January 23, 2022
Decks in 2022
- Shareholder Meeting (November 2022)
Shareholder meeting · 26 slides · Nov 17, 2022
- Investor Presentation (September 2022)
Investor deck · 36 slides · Sep 26, 2022
- Investor Presentation (February 2022)
Investor deck · 35 slides · Feb 1, 2022